The real-world data of the trials showed that patients experienced a 90% reduction in adverse effects associated with marijuana use in comparison with other methods such as oil, smoking, and vaping.
The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial
Syqe®’s third study (2020) evaluated the SyqeAir Inhaler as a solution for safe, consistent, and low-dose medical cannabis treatment in patients with chronic neuropathic pain. Listen to the podcast.
